Scientific Publications
Filter:
Longitudinal Validation of the Artificial Intelligence Algorithm in Home OCT for Age-Related Macular Degeneration—Report 3
Leng T, Leung EH, Mukkamala SK, Taban MR, Havilio M, Nahen K, Mohan N, Benyamini G, Keenan TD. Longitudinal Validation of the Artificial Intelligence Algorithm in Home OCT for Age-Related Macular Degeneration—Report 3. Ophthalmol Sci. 2026; 6(2): 100907. https://doi.org/10.1016/j.xops.2025.100907
Home Monitoring for the Management of Age-Related Macular Degeneration: A Review of the Development and Implementation of Digital Health Solutions over a 25-Year Scientific Journey
Busquets MA, Garfinkel RA, Sambhara D, Mohan N, Nahen K, Benyamini G, Loewenstein A. Home Monitoring for the Management of Age-Related Macular Degeneration: A Review of the Development and Implementation of Digital Health Solutions over a 25-Year Scientific Journey. Medicina. 2025; 61(12):2193. https://doi.org/10.3390/medicina61122193
Home Optical Coherence Tomography-guided Management of Type 3 Macular Neovascularization
Faes, Livia MD1; Holekamp, Nancy MD2; Benyamini, Gidi MBA3; Nahen, Kester PhD3; Mohan, Nishant PhD3; Freund, K. Bailey MD1,4. Home Optical Coherence Tomography-guided Management of Type 3 Macular Neovascularization. Retinal Cases & Brief Reports ():10.1097/ICB.0000000000001792, July 22, 2025. | DOI: 10.1097/ICB.0000000000001792
Pivotal Trial Validating Usability and Visualization Performance of Home OCT in Neovascular Age-related Macular Degeneration
Heier JS, Holekamp NM, Busquets MA, Elman MJ, Schechet SA, Ladd BS, Kapoor KG, Schneider EW, Leung EH, Danis RP, Nahen K, Mohan N, Benyamini G. Pivotal Trial Validating Usability and Visualization Performance of Home OCT in Neovascular Age-related Macular Degeneration. Report 1. Ophthalmol Sci. 2025, 100772. Doi: 10.1016/j.xops.2025.100772.
Pivotal Trial Toward Effectiveness of Self-administered OCT in Neovascular Age-related Macular Degeneration. Report 2—Artificial Intelligence Analytics
Eric W. Schneider MD, Jeffrey S. Heier MD, Nancy M. Holekamp MD, Miguel A. Busquets MD, Alan L. Wagner MD, S. Krishna Mukkamala MD, Christopher D. Riemann MD, Seong Y. Lee MD, Brian C. Joondeph MD, Steven S. Houston MD, et al. Pivotal Trial Toward Effectiveness of Self-administered OCT in Neovascular Age-related Macular Degeneration. Report 2—Artificial Intelligence Analytics. Ophthalmology Science. Volume 5, Issue 2, April 2025, 100662, ISSN 2666-9145. DOI: 10.1016/j.xops.2024.100662
SCANLY Home OCT FDA Intended Use
SCANLY Home OCT has not been approved by FDA for use other than described in the following Intend Use: The Notal Vision Home Optical Coherence Tomography (OCT) System is an Artificial Intelligence (AI)-based Home Use device indicated for visualization of intraretinal and subretinal hypo-reflective spaces in a 10 by 10-degrees area centered on the point of fixation of eyes diagnosed with neovascular age-related macular degeneration (NV-AMD). In addition, it provides segmentation and an estimation of the volume of hypo-reflective spaces. The Notal Home OCT device is intended for imaging at home between regularly scheduled clinic assessments and not intended to be used to make treatment decisions or replace standard-of care regularly scheduled examinations and clinical testing as needed, including in-office imaging and assessments for changes in vision, by an ophthalmologist.
See also Warnings and Precautions.
ForeseeHome FDA Intended Use
ForeseeHome has not been approved by FDA for use other than described in the following Indication for Use: The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.
